Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDRH FY 1997 salaries/expenses budget of $170.9 mil. recommended by House subcommittee.

This article was originally published in The Gray Sheet

Executive Summary

CDRH FISCAL 1997 BUDGET RECOMMENDATION TOTALS $170.9 MIL., as passed through the House Appropriations/Agriculture Subcommittee mark-up May 21. The recommended salary and expense budget for FDA's Center for Devices and Radiological Health represents a $4.3 mil. increase from CDRH's fiscal 1996 enacted salaries and expenses appropriation of $166.5 mil. and a slight increase -- $775,000 -- over FDA's fiscal 1997 budget request of $170.1 mil. Full Appropriations Committee mark-up is expected to be held June 6.

You may also be interested in...



Pipeline Watch: Five Approvals And 23 Phase III Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT006060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel